Predictors of Major Atrial Fibrillation Endpoints in the National Heart, Lung, and Blood Institute HCMR

  • Christopher M. Kramer* (Corresponding Author)
  • , John P. DiMarco
  • , Paul Kolm
  • , Carolyn Y. Ho
  • , Milind Y. Desai
  • , Raymond Y. Kwong
  • , Sarahfaye F. Dolman
  • , Patrice Desvigne-Nickens
  • , Nancy Geller
  • , Dong Yun Kim
  • , Martin S. Maron
  • , Evan Appelbaum
  • , Michael Jerosch-Herold
  • , Matthias G. Friedrich
  • , Jeanette Schulz-Menger
  • , Stefan K. Piechnik
  • , Masliza Mahmod
  • , Daniel Jacoby
  • , James White
  • , Amedeo Chiribiri
  • Adam Helms, Lubna Choudhury, Michelle Michels, William Bradlow, Michael Salerno, Dana K. Dawson, Jonathan W. Weinsaft, Colin Berry, Sherif F. Nagueh, Chiara Buccarelli-Ducci, Anjali Owens, Barbara Casadei, Hugh Watkins, William S. Weintraub, Stefan Neubauer, HCMR Investigators
*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)

Abstract

Objectives: This study sought to identify predictors of major clinically important atrial fibrillation endpoints in hypertrophic cardiomyopathy. Background: Atrial fibrillation (AF) is a common morbidity associated with hypertrophic cardiomyopathy (HCM). The HCMR (Hypertrophic Cardiomyopathy Registry) trial is a prospective natural history study of 2,755 patients with HCM with comprehensive phenotyping. Methods: All patients received yearly telephone follow-up. Major AF endpoints were defined as requiring electrical cardioversion, catheter ablation, hospitalization for >24 h, or clinical decisions to accept permanent AF. Penalized regression via elastic-net methodology identified the most important predictors of major AF endpoints from 46 variables. This was applied to 10 datasets, and the variables were ranked. Predictors that appeared in all 10 sets were then used in a Cox model for competing risks and analyzed as time to first event. Results: Data from 2,631 (95.5%) patients were available for analysis after exclusions. A total of 127 major AF endpoints events occurred in 96 patients over 33.3 ± 12.4 months. In the final model, age, body mass index (BMI), left atrial (LA) volume index, LA contractile percent (active contraction), moderate or severe mitral regurgitation (MR), and history of arrhythmia the most important. BMI, LA volume index, and LA contractile percent were age-dependent. Obesity was a stronger risk factor in younger patients. Increased LA volume, reduced LA contractile percent, and moderate or severe MR put middle-aged and older adult patients at increased risk. Conclusions: The major predictors of major AF endpoints in HCM include older age, high BMI, moderate or severe MR, history of arrhythmia, increased LA volume, and reduced LA contractile percent. Prospective testing of a risk score based on these parameters may be warranted.

Original languageEnglish
Pages (from-to)1376-1386
Number of pages11
JournalJACC: Clinical Electrophysiology
Volume7
Issue number11
Early online date30 Jun 2021
DOIs
Publication statusPublished - 1 Nov 2021

Bibliographical note

Funding Information:
This work was supported by the National Institutes of Health, the National Heart, Lung, and Blood Institute (U01HL117006-01A1) and the Oxford NIHR Biomedical Research Centre. Dr. Kramer has received research grants from MyoKardia and Cytokinetics; and has been consultant for MyoKardia and Cytokinetics. Dr. DiMarco has been a consultant to Novartis, Galmed, and Celgene. Dr. Ho has been consultant for and has received research support from MyoKardia. Dr. Kwong has received research support from Siemens Healthineers, Bayer AG, and Myokardia. Dr. Maron has received consulting and research support from iRhythm; and has been a consultant for Celltrion and Cytokinetics. Dr. Friedrich has been a board member, shareholder, and consultant of Circle Cardiovascular Imaging Inc. Dr. Schulz-Menger has been a consultant for Bayer; has received research grants from Bayer, Siemens Healthineers, and Circle Cardiovascular Imaging. Dr. Piechnik holds U.S. patent 9,285,446 B2: “Systems and methods for shortened look locker inversion recovery (Sh-MOLLI) cardiac gated mapping of T1.” Dr. Jacoby has been consultant for and has received a research grant from MyoKardia. Dr. White holds shares in Cohesic; and has received a research grant from Siemens Healthineers. Dr. Chiribiri has received research grants from Philips Healthcare and Siemens Healthineers. Dr. Helms has received research support from MyoKardia. Dr. Bradlow has received honoraria from Daichi-Sankyo. Dr. Salerno has received research support from Siemens Healthineers and Heartflow. Dr. Dawson has received research grant from Philips Healthcare. Dr. Nagueh has been a consultant for MyoKardia. Dr. Casadei has received research support from Roche Diagnostics and iRhythm. Dr. Watkins has been a consultant for Cytokinetics. Dr. Neubauer has received research grants from Boehringer Ingelheim and Cytokinetics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Publisher Copyright:
© 2021 American College of Cardiology Foundation

Data Availability Statement

Supplemental Data: For a list of HCMR investigators, an expanded Methods section, and supplemental tables and figures, please see the online version of this paper.

Funding

This work was supported by the National Institutes of Health, the National Heart, Lung, and Blood Institute (U01HL117006-01A1) and the Oxford NIHR Biomedical Research Centre. Dr. Kramer has received research grants from MyoKardia and Cytokinetics; and has been consultant for MyoKardia and Cytokinetics. Dr. DiMarco has been a consultant to Novartis, Galmed, and Celgene. Dr. Ho has been consultant for and has received research support from MyoKardia. Dr. Kwong has received research support from Siemens Healthineers, Bayer AG, and Myokardia. Dr. Maron has received consulting and research support from iRhythm; and has been a consultant for Celltrion and Cytokinetics. Dr. Friedrich has been a board member, shareholder, and consultant of Circle Cardiovascular Imaging Inc. Dr. Schulz-Menger has been a consultant for Bayer; has received research grants from Bayer, Siemens Healthineers, and Circle Cardiovascular Imaging. Dr. Piechnik holds U.S. patent 9,285,446 B2: “Systems and methods for shortened look locker inversion recovery (Sh-MOLLI) cardiac gated mapping of T1.” Dr. Jacoby has been consultant for and has received a research grant from MyoKardia. Dr. White holds shares in Cohesic; and has received a research grant from Siemens Healthineers. Dr. Chiribiri has received research grants from Philips Healthcare and Siemens Healthineers. Dr. Helms has received research support from MyoKardia. Dr. Bradlow has received honoraria from Daichi-Sankyo. Dr. Salerno has received research support from Siemens Healthineers and Heartflow. Dr. Dawson has received research grant from Philips Healthcare. Dr. Nagueh has been a consultant for MyoKardia. Dr. Casadei has received research support from Roche Diagnostics and iRhythm. Dr. Watkins has been a consultant for Cytokinetics. Dr. Neubauer has received research grants from Boehringer Ingelheim and Cytokinetics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Keywords

  • atrial fibrillation
  • hypertrophic cardiomyopathy
  • left atrium
  • MRI

Fingerprint

Dive into the research topics of 'Predictors of Major Atrial Fibrillation Endpoints in the National Heart, Lung, and Blood Institute HCMR'. Together they form a unique fingerprint.

Cite this